

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Rimegepant (Nurtec)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial of a triptan is use in at least 3 migraine episodes. Pain reduction in at least 2 episodes is considered effective.

Initiation (new start) criteria, and criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **rimegepant (Nurtec)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by neurologist **AND**
- Patient is at least 18 years old **AND**
- Prescribed for the treatment of acute migraine **OR** migraine prophylaxis **AND**
- Documented past medication trials as outlined below:
 - Acute migraine:
 - Patient has failed a trial[^] of or has an allergy or intolerance to at least 3 triptans at maximum tolerated doses **OR** patient has documented contraindication to triptan use (i.e. coronary artery disease, history of ischemic stroke due to atherosclerosis, peripheral vascular disease, uncontrolled hypertension) **AND**
 - Patient has failed a trial of or has an allergy or intolerance to ubrogepant (Ubrelvy)
 - Migraine prophylaxis:
 - Patient has failed an adequate trial of, or patient has an allergy or intolerance to 3 additional preventative agents for migraine, 2 of which must include: tricyclic antidepressant (amitriptyline or nortriptyline), or beta-blocker (metoprolol or propranolol), or valproate, or topiramate **AND**
 - Patient has failed a trial of, or has an allergy or intolerance to fremanezumab (Ajovy), **AND** galcanezumab (Emgality) **AND** erenumab (Aimovig)
 - Patient has failed a trial of, or has an allergy or intolerance to atogepant (Qulipta)

kp.org

Revised: 03/09/23
Effective: 05/04/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Rimegepant (Nurtec)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary rimegepant (Nurtec) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient is at least 18 years old **AND**
- Prescribed for the treatment of acute migraine **OR** migraine prophylaxis **AND**
- Documented past medication trials as outlined below:
 - Acute migraine:
 - Patient has failed a trial of or has an allergy or intolerance to at least 3 triptans at maximum tolerated doses **OR** patient has documented contraindication to triptan use (i.e. coronary artery disease, history of ischemic stroke due to atherosclerosis, peripheral vascular disease, uncontrolled hypertension) **AND**
 - Patient has failed a trial of or has an allergy or intolerance to ubrogepant (Ubrovelvy)
 - Migraine prophylaxis:
 - Patient has failed a trial of, or has an allergy or intolerance to fremanezumab (Ajovy), **AND** galcanezumab (Emgality) **AND** erenumab (Aimovig)
 - Patient has failed a trial of, or has an allergy or intolerance to atogepant (Qulipta)

Continued use criteria for patients stable on the medication: Non-formulary Rimegepant (Nurtec) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a neurology provider